Introduction
Total number of EEFs was counted in one well of an 8-well permanox Lab-Tek chamber 147 slide system (Nunc). Percentages were obtained as a ratio of either 6-Fam-octaarginine 148 positive EEFs to the total number or of 6-Fam-octaarginine negative EEFs to the total 149 number. Mean values of three biological replicates were plotted. 150
151

Plaque assay 152
For the plaque assay, HFF cells in 6-well plates were infected with T. gondii tachyzoites 153 in presence of the corresponding drug, cultured for 7 days, fixed with -80°C methanol, 154 stained with crystal violet and documented using a Zeiss microscope at 5x magnification 155
objective. Experiments were performed in three independent replicates. For tachyzoite 156 pre-treatment assay, freshly harvested T. gondii tachyzoites were pre-incubated with the 157 corresponding drug for 1 hour in a CO 2 incubator at 37°C prior to infection of HFF cells. 158
159
Growth inhibition assay of blood stage P. falciparum 160
Pf clone 3D7 was cultured at 5% hematocrit of human O + red blood cells in RPMI 1640 161 supplemented with 0.05 g/liter hypoxanthine (Sigma-Aldrich), 25 mM Hepes, 0.5% 162 Albumax II (Life Technologies), 0.25% sodium bicarbonate, and 0.01 mg/ml gentamicin 163 (Sigma-Aldrich). All cultures were kept at 37°C under 90% nitrogen, 5% oxygen, and 5% 164 carbon dioxide. Cultures were treated with fosmidomycin or fosmidomycin-octaarginine 165 conjugates at various concentrations indicated. Experiments were done in triplicates for 166 72 h. Medium was changed daily, and blood smears were prepared every 24 h to 167 monitor parasitaemia. Briefly, samples were fixed with methanol and stained with 168 on September 23, 2017 by guest http://aac.asm.org/
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Nunc International Corp) at a density of 50 000 cells/well. On the next day, cells were 174 infected with 10,000 freshly dissected P. berghei sporozoites per well. 24 h after 175 infection either fosmidomycin or the fosmidomycin-octaarginine conjugate 2 were added 176 at various concentrations. Merosomes were isolated from cell culture supernatant 65 h 177 after infection and counted. Mean number of merosomes was generated from three 178 independent wells of an 8-well Lab-Tek permanox chamber slide system (Nunc). Chemical synthesis of Fosmidomycin-octaarginine conjugates28) (A in Fig. 1) . In some cases the carrier peptide was built of D-instead of the natural 198 L-aminoacids in order to prevent premature degradation (24, 29, 30) . In other cases 199 proteolytically stable CPPs containing -oligoarginines or lysines were used (31-36) (B 200 in Fig. 1 
). 201
Recently, Matile and his group have introduced a conceptually new mode of non-202 covalent attachment of the carrier CPP to a cargo (37, 38), namely salt formation of the 203 guanidinium cations of the CPP with carboxylate anions of a cargo (C in Fig. 1) . 204
Anticipating that a similar, possibly even stronger ionic interaction would occur with a 205 phosphate anion such as in fosmidomycin and its analogues (D in Fig. 1 ), we generated 206 the salt (compound 2) of 6-Fam-labeled octaarginine amide (compound 1) with four 207 fosmidomycin units by mixing the two compounds in water and lyophilizing the resulting 208 solution (Fig. 1) . 209
In another approach of carrying fosmidomycin or FR900098 into infected cells we 210 envisioned that acylation on oxygen of the hydroxylamine moiety might produce an 211 active ester, from which the antibiotic could be released. We expected that the 212 phosphonate ester group would also be hydrolyzed, since both, the free phosphonic 213 acid and the free N(OH)COR group are believed to be essential for binding to the DXR 214 enzyme target. Thus, we also generated the octaarginine amide carrying one (Fig. 2B) . 232 233
Uptake of 6-Fam-octaarginine by Plasmodium-infected cells 234
Previous work established that fosmidomycin is efficiently transported into P. falciparum-235 infected erythrocytes through the parasite-induced new permeability pathways (22). In 236 order to estimate the potential of octaarginine to serve as carrier for drug delivery, we 237 first evaluated its ability to cross the multiple membrane barriers separating the parasite 238 from the extracellular compartment. Plasmodium species are obligate intracellular 239 pathogens that reside inside a parasitophorous vacuole (PV) in the cytoplasm of the 240 Plasmodium berghei-infected human liver cell line (Huh7) representing the 246 exoerythrocytic form (EEF) of the parasite (Fig. 3A and Fig. 4A ). In line with our 247 previous findings (10), 6-Fam-octaarginine (compound 1) efficiently penetrated infected 248 red blood cells. After 12 h of incubation most of the fluorescent signal was located within 249 the PV (Fig. 3A) . In contrast to P. falciparum-infected erythrocytes, where virtually every 250 infected cell incorporated the peptide, in P. berghei infected hepatoma cells peptide 251 uptake was not complete, and a subset of infected cells (30%) did not incorporate the 252 peptide ( Fig. 4A and 4B) . Together, the findings show that 6-Fam-octaarginine 253 (compound 1) is able to cross various biological membranes. 254
255
Conjugation of octaarginine to fosmidomycin improves efficacy against P. 256 falciparum asexual blood stages 257
We next evaluated the potential of octaarginine to deliver fosmidomycin into target cells. 258
Growth inhibition assays were performed in the presence of fosmidomycin or its 259 octaarginine conjugates (salt 2 or conjugate 3). First we tested whether combining 260 fosmidomycin to octaarginine could enhance the inhibitory effect of fosmidomycin on 261 blood stage P. falciparum ( When the covalently attached FR-900098-octaarginine conjugate 3 was tested 268 the inhibitory effect on parasite growth was weaker in comparison to the salt complex or 269 fosmidomycin ( Fig. 3E) , suggesting that FR-900098 was, at least in this experimental 270 setup, only partially released from the covalent derivative (conjugate 3). The observed 271 significant activity at lower concentration (0.1 and 0.5 M) indicated that the active 272 antibiotic must have become available. In order to quantify how octaarginine improves 273 the efficacy of fosmidomycin we calculated the IC 50 values of the salt complex 2 in 274 comparison to fosmidomycin (Fig 3F) . Growth inhibition experiments with either 275 fosmidomycin or the salt conjugate 2 were performed over a concentration range of 1 276 nM to 5 M. The IC 50 value of the salt complex 2 was 4.4 nM, compared to a 181 nM for 277 free fosmidomycin (Fig. 3F) . Hence, the 40-fold increase in activity could be attributed 278 directly to the addition of octaarginine. 279
A previous report described a broad-spectrum activity of TP10, a fragment of the 280 cell penetrating peptide transportan against P. falciparum and the kinetoplastid 281 protozoan parasite Trypanosoma brucei (39). In order test whether the observed 282 improved efficacy of fosmidomycin in combination with octaarginine was a result of a 283 potential synergistic growth inhibitory property of octaarginine, we included control 284 experiments with 6-Fam-octaarginine alone (Fig. 3C) . We found that the use of up to 285 100 M of 6-Fam-octaarginine has no effect on the growth of P. falciparum. This result 286 supports the notion that octaarginine acts as delivery vehicle only. Our results also 287 penetrating peptides. 292 293 Fosmidomycin-octaarginine complex displays activity against P. berghei pre-294
erythrocytic stages 295
We next investigated the effect of fosmidomycin-octaarginine salt complex 2 on liver 296 stage parasites. There have been contradictory reports on the ability of fosmidomycin to 297 inhibit the growth of liver stage P. berghei. While two studies claimed a complete lack of 298 activity on liver stage parasite, presumably due to poor drug uptake (22, 40), another 299 study reported significant inhibition of apicoplast biogenesis in liver stage parasites and 300 as a consequence, merosome formation at 10 M fosmidomycin (21). 301
In order to test enhanced causal-prophylactic efficacy of fosmidomycin 302 conjugation to octaarginine on liver stage parasites, we monitored P. berghei liver stage 303 development in the presence of fosmidomycin or its octaarginine salt complex 2 (Fig. 4) . 304
We assessed liver stage size and morphology and the number of merosomes, which 305 represent the final stage of pre-erythrocytic development. We did not observe any 306 apparent changes in the morphology liver stages in the presence of either fosmidomycin 307 or the salt complex (data not shown). Enumeration of merosomes 65 h after infection 308 revealed a moderate, but significant reduction when either 10 M or 100 M -309 fosmidomycin-octaarginine salt complex 2 was applied (Fig. 4C) . In marked contrast, 310 addition of fosmidomycin alone had no effect (Fig. 4C) . Of note, the inhibitory activity of 311 on September 23, 2017 by guest http://aac.asm.org/ Downloaded from we failed to achieve full inhibition of merosome release even at higher concentrations 313 (data not shown). This incapacity to fully inhibit Plasmodium liver stage growth might be, 314 at least partially, explained by the observed incomplete uptake of 6-Fam-octaarginine 315
into Plasmodium-infected hepatoma cells (Fig. 4B) . In conclusion these findings provide 316 chemical genetics evidence for an important function of the non-mevalonate isoprenoid 317 biosynthesis pathway in pre-erythrocytic development of the malaria parasite. 318
319
Inhibition of extracellular Toxoplasma gondii tachyzoites by the fosmidomycin-320
octaarginine complex 321
To independently confirm the carrier function of octaarginine in anti-parasitic drug 322 delivery we decided to extend our investigation to Toxoplasma gondii another 323 apicomplexan parasite and the causative agent of toxoplasmosis. Recent data 324 demonstrated that T. gondii DXR is required for parasite growth (21). We first tested 325 whether 6-Fam-octaarginine can enter T. gondii-infected human foreskin fibroblasts 326 (HFFs) (Fig. 5A) . When T. gondii-infected HFFs were grown in presence of 6-Fam-327 octaarginine, the fluorescently labeled peptide was excluded from the parasitophorous 328 vacuole although it was clearly visible in the cytosol of the host cell. These data indicate 329 that only the first membrane barrier, i.e the host plasma membrane, can be overcome by 330 the octaarginine carrier. Next, we investigated the ability of the fosmidomycin-331 octaarginine complex 2 to inhibit the intracellular growth of T. gondii (Fig. 5B, 5C) . 332
Neither fosmidomycin nor the salt conjugate had a significant effect on parasite growth. 333
This result is probably a direct consequence of the inability of 6-Fam-octaarginine to 334 penetrate the parasitophorous vacuole (PV) of T. gondii (Fig. 5A) . 335 on September 23, 2017 by guest http://aac.asm.org/ Downloaded from gondii tachyzoites in the presence of fosmidomycin or fosmidomycin-octaarginine salt 337 complex 2 for 1 h prior to infection of fresh HFFs (Fig. 5D, 5E) . Pretreatment of 338 tachyzoites with up to 100 M of fosmidomycin had no effect on parasite growth, 339
confirming that fosmidomycin does not cross the parasite plasma membrane. In marked 340 contrast, pretreatment with fosmidomycin-octaarginine salt complex 2 led to a 341 concentration-dependent inhibition of parasite growth with a pronounced inhibition 342 already at 1 M. This result shows that the PV membrane but not the parasite 343 membrane constitutes the major barrier to the fosmidomycin-octaarginine complex in 344 intracellular T. gondii. 345
346
Octaarginine derivatives render fosmidomycin effective against mycobacteria 347
Reversal of refractoriness to fosmidomycin of T. gondii tachyzoites and P. berghei liver 348 stages by the octaarginine salt complex 2 prompted us to extend our study to a different 349 fosmidomycin in enzyme assays (41). However, growth of the pathogen is not affected 367 by fosmidomycin presumably due to a poor uptake of the drug by bacteria (20) . 368
Based on our observation that mycobacteria are highly permeable to 6-Fam-369 octaarginine (Fig. 6A, 6B) , we hypothesized that combination of fosmidomycin and 370 octaarginine could improve drug uptake and thereby increase susceptibility of 371 mycobacteria. We monitored the growth of non-pathogenic M. bovis BCG in the 372 presence of fosmidomycin alone or in combination with octaarginine (salt 2 and 373 conjugate 3) and used isoniazid as positive control (Fig. 6) . Mycobacterial growth was 374 reduced when fosmidomycin was combined to octaarginine in either non-covalent (Fig.  375 6E) or covalent form (Fig. 6F) . When octaarginine alone or unmodified fosmidomycin 376 were used, mycobacterial growth remained unaffected (Fig. 6C, 6D) . In contrast to our 377 findings in apicomplexan parasites, the covalently linked fosmidomycin-octaarginine 378 conjugate 3 showed significant inhibition in mycobacteria (Fig. 6F) . 379 Discussion uptake. In the present study, we have overcome the restriction of fosmidomycin by 386 carrier-mediated delivery to intracellular pathogens. We evaluated the potential of 387 octaarginine, a polycationic cell penetrating peptide, as a delivery vehicle for 388 fosmidomycin to improve efficacy. We hypothesized that octaarginine might improve the 389 delivery of fosmidomycin across the multiple biological membranes separating the target 390 compartment of intracellular pathogens from the extracellular space. Our investigations 391
show that the combination of octaarginine and fosmidomycin dramatically increases its 392 efficacy towards blood stage P. falciparum. In addition, the fosmidomycin-octaarginine 393 combination has a significant inhibitory effect on maturation of liver stage P. berghei, 394 whereas up to 100 M of fosmidomycin alone had no effect. We note that these results 395 are in opposition to a previous report by Nair et al., which claimed a significant effect on 396 merosome formation of P. berghei at 10 M of fosmidomycin (21) but in full support of 397 studies that show no efficacy against P. berghei liver stages (22, 40) . 398
We observed a strict correlation between the permeability of a given cell type to 399 octaarginine and its ability to improve efficacy of fosmidomycin in these cells. When 400 octaarginine was unable to cross a biological membrane, the pathogen beyond this 401 barrier remained unaffected by fosmidomcyin-octaarginine conjugates. This was, for 402 example, the case for intracellular T. gondii. In these cells, 6-Fam-octaarginine did not 403 penetrate the PV, which correlates with their resistance to the fosmidomycin-404 on September 23, 2017 by guest http://aac.asm.org/ Downloaded from concentration-dependent sensitivity toward the fosmidomycin-octaarginine complex. We 407 speculate that the limited activity of the fosmidomycin-octaarginine complex against liver 408 stage P. berghei is probably also a consequence of the incomplete uptake of the 409 peptide. These results suggest that both, the PVM and the parasite plasma membrane, 410 are critical barriers to fosmidomycin in liver stage P. berghei and, most importantly, in 411
T.gondii-infected host cells. The carrier peptide 6-Fam-octaarginine used in this study, 412 has a molecular weight of 1.6 kDa, which is well above the proposed cut off of 1.2 kDa 413 for the PVM of T. gondii-infected cells (42), probably explaining the inability of this 414 molecule to penetrate the PV. Strikingly, the observation that the PVM of both, blood 415 stage and liver stage Plasmodium species are permeable to 6-Fam-octaarginine might 416 hint at a PVM-resident transport protein operating in Plasmodium parasites. Patch clamp 417 experiments identified a solute pore in blood stage parasites that is permeable to 418 molecules up to the size of 1.4 kDa, which is again below the size of 6-Fam-octaarginine 419 (43, 44). The apparent different permeability of the Plasmodium-as compared to the T. 420 gondii-PVM is best explained by a distinct carrier in the Plasmodium PVM, which is 421 known to be particularly rich in species-specific proteins (45). Although a previous study 422 has reported a successful application of oligoarginine for the delivery of triclosan against 423 both extracellular and intracellular forms of T. gondii (24), we did not observe a 424 permeability of the T. gondii PVM for octaarginine. 425
The application of octaarginine as a versatile delivery vehicle for fosmidomycin 426 was further broadened by our finding that mycobacterial fosmidomycin resistance could 427 be reverted by combining the drug with octaarginine. Interestingly, both the non-covalent 
